Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a

Publication date: Available online 18 August 2017
Source:Clinical Immunology
Author(s): Roberta Lanzillo, Fortunata Carbone, Mario Quarantelli, Dario Bruzzese, Antonio Carotenuto, Veronica De Rosa, Alessandra Colamatteo, Teresa Micillo, Carla De Luca Picione, Francesco Saccà, Anna De Rosa, Marcello Moccia, Vincenzo Brescia Morra, Giuseppe Matarese
Reliable immunologic biomarkers able to monitor disease course during multiple sclerosis (MS) are still missing. We aimed at identifying possible immunometabolic biomarkers able to predict the clinical outcome in MS patients during treatment with interferon (IFN)-beta-1a. We measured in 45 relapsing-remitting (RR) MS patients, blood circulating levels of several immunometabolic markers, at enrolment, and correlated their levels to disease activity and progression over time. Higher levels of interleukin (IL)-6, soluble-CD40-ligand (sCD40L) and leptin at baseline associated with a higher relapse rate and a greater risk of experiencing at least one relapse in the following year. Higher values of soluble tumor necrosis factor receptor (sTNF-R) and leptin at baseline were predictive of a higher number of lesions in the following one-year of follow up. Our data suggest that an immunometabolic screening measuring IL-6, sCD40L, leptin and sTNF-R at baseline, before starting IFN-beta-1a, is able to predict a poor response to treatment.



http://ift.tt/2wfQYYh